SciClone Pharmaceuticals, Inc. (SCLN) and Sigma-Tau S.p.A. announced that all 553 enrolled patients successfully completed a Phase 3 trial. After 48 weeks of therapy, all patients responding to treatment have now completed their 24-week follow-up.
The Phase 3 trial is evaluating ZADAXIN in combination with pegylated interferon alpha and ribavirin as a treatment for patients with hepatitis C virus.
The unblinded data from the trial are expected to be available in the fourth quarter of 2008.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.